| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
trans-11-Eicosenoic acid does not have a defined pharmacological target as it is a biochemical research reagent rather than a therapeutic agent. However, studies have demonstrated that it can inhibit glycerophosphate acyltransferase, cholinephosphotransferase, and ethanolaminephosphotransferase in V79-R cells. These enzymes are involved in phospholipid biosynthesis pathways. As a fatty acid, it may also interact with fatty acid-binding proteins and membrane lipid bilayers through hydrophobic interactions. Its trans configuration distinguishes it from natural cis-fatty acids and may affect its membrane fluidity-modulating properties.
|
|---|---|
| ln Vitro |
In vitro, trans-11-Eicosenoic acid has been shown to inhibit key enzymes involved in phospholipid synthesis, including glycerophosphate acyltransferase, cholinephosphotransferase, and ethanolaminephosphotransferase, in V79-R Chinese hamster lung fibroblast cells. This enzyme inhibition suggests that the compound can modulate lipid metabolism in cultured cells. The compound is also used as a biochemical reagent to study phospholipid membrane structure and function. No specific cytotoxicity or cell viability data are available, but as a fatty acid, it is expected to be incorporated into cellular membranes and may affect membrane properties.
|
| ln Vivo |
trans-11-Eicosenoic acid is not a pharmacologically active drug and therefore does not exhibit in vivo therapeutic activity. It has not been evaluated in animal models for efficacy against any disease. The compound is primarily used as a research standard for fatty acid analysis and as a biochemical reagent to study lipid metabolism and membrane biology. As a component of jojoba seed oil, where C20:1 isomers constitute up to 70% of the total fatty acid pool, it may have nutritional or cosmetic applications, but no pharmacological effects have been reported.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for trans-11-Eicosenoic acid typically involve incubating the compound with enzyme preparations and measuring enzymatic activity using radiolabeled or colorimetric substrates. For glycerophosphate acyltransferase inhibition studies, V79-R cell homogenates are incubated with [¹⁴C]-glycerol-3-phosphate and palmitoyl-CoA in the presence of varying concentrations of the test fatty acid. Reactions are terminated by extraction, and labeled products are quantified by scintillation counting. For cholinephosphotransferase and ethanolaminephosphotransferase assays, similar protocols using CDP-[¹⁴C]-choline or CDP-[¹⁴C]-ethanolamine as substrates are employed.
|
| Cell Assay |
In vitro cell culture experiments with trans-11-Eicosenoic acid utilize V79-R Chinese hamster lung fibroblast cells cultured in standard media supplemented with fetal bovine serum. Cells are grown to confluence in 6-well or 12-well plates, and the fatty acid is delivered to cells as a complex with fatty acid-free bovine serum albumin to enhance solubility. Cells are treated with the compound at concentrations ranging from 10-100 µM for 24-48 hours. Following treatment, cells are harvested, homogenized, and enzyme activities are measured. Cell viability can be assessed using trypan blue exclusion or MTT assays to ensure that observed effects are not due to cytotoxicity.
|
| Animal Protocol |
In vivo animal studies with trans-11-Eicosenoic acid are not documented in the literature, as the compound is a research reagent rather than a drug candidate. If used in animal studies, a typical protocol for fatty acid administration would involve oral gavage or intravenous injection in rodents at doses ranging from 10-100 mg/kg. Blood samples would be collected at various time points for pharmacokinetic analysis, and tissues would be harvested for lipid profiling. Animals would be monitored for clinical signs, body weight changes, and food intake. However, such studies have not been reported for this specific compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of trans-11-Eicosenoic acid are not well characterized. As a long-chain fatty acid with a molecular weight of 310.51 and high lipophilicity (predicted LogP 8.44), the compound is expected to be absorbed through the gastrointestinal tract via incorporation into chylomicrons. Following absorption, it would be distributed to various tissues, incorporated into cellular membranes, and metabolized via β-oxidation. The compound has very low water solubility (5.6×10⁻⁴ g/L), which would limit its bioavailability. The trans double bond may affect its metabolism compared to cis-isomers. No formal ADME studies have been conducted.
|
| Toxicity/Toxicokinetics |
Toxicological data for trans-11-Eicosenoic acid are limited. As a naturally occurring fatty acid found in jojoba oil, it is generally considered safe for topical and nutritional applications at normal dietary levels. The compound has a WGK Germany classification of 3 and a storage class of 11 (combustible solids). Standard laboratory precautions should be followed when handling the compound. It should be stored at -20°C. No acute toxicity, mutagenicity, or carcinogenicity data are available. The compound is not intended for drug use and has not undergone formal toxicological evaluation.
|
| Additional Infomation |
Trans-eicosenoic acid (TEA) is a long-chain fatty acid. It has been reported in Hoya crassipes, Hoya pseudolanceolata, and other organisms with relevant data. See also: Eicosenoic acid (note moved to); trans-2-eicosenoic acid (note moved to).
trans-11-Eicosenoic acid is a monounsaturated fatty acid that is a trans isomer of arachidic acid. It is also known as 11-trans-Eicosenoic acid and trans-gondoic acid. The compound is available as a high-purity (≥98%) analytical standard for lipid research. It is one of several monounsaturated C20:1 fatty acids. The compound has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action in enzyme inhibition involves interference with phospholipid biosynthesis pathways. It is used exclusively for laboratory research purposes. |
| Molecular Formula |
C20H38O2
|
|---|---|
| Molecular Weight |
310.51
|
| Exact Mass |
310.287
|
| CAS # |
62322-84-3
|
| PubChem CID |
5282769
|
| Appearance |
White to off-white solid powder
|
| Density |
0.895 g/cm3
|
| Boiling Point |
426.3ºC at 760 mmHg
|
| Melting Point |
52-53℃
|
| Flash Point |
110ºC
|
| Index of Refraction |
1.467
|
| LogP |
6.888
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
22
|
| Complexity |
258
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC\C=C\CCCCCCCCCC(O)=O
|
| InChi Key |
BITHHVVYSMSWAG-MDZDMXLPSA-N
|
| InChi Code |
InChI=1S/C20H38O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h9-10H,2-8,11-19H2,1H3,(H,21,22)/b10-9+
|
| Chemical Name |
(E)-icos-11-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (322.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.05 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2205 mL | 16.1025 mL | 32.2051 mL | |
| 5 mM | 0.6441 mL | 3.2205 mL | 6.4410 mL | |
| 10 mM | 0.3221 mL | 1.6103 mL | 3.2205 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
